Thrombosis with Thrombocytopenia Syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination – A risk–benefit analysis for people < 60 years in Australia

The AstraZeneca ChAdOx1 nCoV-19 (AZD1222) vaccine is associated with Thrombosis with Thrombocytopenia Syndrome (TTS) in 3/100,000 vaccinations with high fatality rates reported in many countries. We conducted a risk–benefit analysis for Australians aged 18–59 years, comparing the risk of vaccination...

Descripción completa

Detalles Bibliográficos
Autores principales: MacIntyre, Chandini Raina, Veness, Benjamin, Berger, David, Hamad, Nada, Bari, Noor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270740/
https://www.ncbi.nlm.nih.gov/pubmed/34272095
http://dx.doi.org/10.1016/j.vaccine.2021.07.013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270740/
https://www.ncbi.nlm.nih.gov/pubmed/34272095
http://dx.doi.org/10.1016/j.vaccine.2021.07.013

Ejemplares similares